The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
about
Developmental consequences of perinatal cannabis exposure: behavioral and neuroendocrine effects in adult rodentsChemical probes of endocannabinoid metabolismPolymodal activation of the endocannabinoid system in the extended amygdalaSubstrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activationSelective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents.Cannabis as a substitute for prescription drugs - a cross-sectional studySimulation of Swanson's literature-based discovery: anandamide treatment inhibits growth of gastric cancer cells in vitro and in silico.Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain.Animal models of cannabinoid reward.Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructureCannabinoid modulation of subgenual anterior cingulate cortex activation during experience of negative affect.Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient micePharmacological blockade of the fatty acid amide hydrolase (FAAH) alters neural proliferation, apoptosis and gliosis in the rat hippocampus, hypothalamus and striatum in a negative energy context.Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.Alcohol Versus Cannabinoids: A Review of Their Opposite Neuro-Immunomodulatory Effects and Future Therapeutic PotentialsAcute stress increases circulating anandamide and other N-acylethanolamines in healthy humans.Cannabinoid facilitation of fear extinction memory recall in humans.Study the Effect of Endocannabinoid System on Rat Behavior in Elevated Plus-MazeNeurobiological Interactions Between Stress and the Endocannabinoid System.Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety.Endocannabinoid regulation of nausea is mediated by 2-arachidonoylglycerol (2-AG) in the rat visceral insular cortex.Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman PrimatesSynthesis and Preliminary PET Imaging Studies of a FAAH Radiotracer ([¹¹C]MPPO) Based on α-Ketoheterocyclic Scaffold.Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.Targeted alterations in dietary n-3 and n-6 fatty acids improve life functioning and reduce psychological distress among patients with chronic headache: a secondary analysis of a randomized trial.Supply and demand for endocannabinoids.Using dopamine research to generate rational cannabinoid drug policy.A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy.Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling.The Role of the Endocannabinoid System and Genetic Variation in Adolescent Brain Development.Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase.Interactions Between Anandamide and Corticotropin-Releasing Factor Signaling Modulate Human Amygdala Function and Risk for Anxiety Disorders: An Imaging Genetics Strategy for Modeling Molecular InteractionsIdentification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitorCovalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas.Cannabinoid CB1 Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors.
P2860
Q24613945-947D7950-59E9-4D41-A823-40AF0A7EE39EQ26863202-74DACF2F-807B-4B05-8BAB-B656BC3A3AD2Q28252319-4AB7C40F-5435-4C98-B480-C1E3E64DE20CQ30547823-F53EECC6-CFBA-41D0-9786-BE7D087859CEQ30612936-F05BF852-E040-414D-8A6E-FCAB05B8F79BQ33650518-BC4573AC-FD60-4B1A-BD34-F43573CAF853Q33784314-5B35333B-BAA9-48FE-8923-B7D4CBD63538Q34041284-258A21B1-3878-4B74-B1A6-3CA6DCAA1E05Q34098204-B2F27DA3-55AD-4F69-8544-E42262BEFB02Q34104954-6FAD8DB1-73B5-4632-93F1-23146CD61643Q34565978-C986E482-86D5-48C7-911A-CFC65B142EA7Q34608846-1E161280-74B7-4BC4-B224-37F24763B253Q35222716-8DB4C651-DAB3-475D-8889-518ECE0BAE26Q35532072-2A5514EB-389B-42F4-8161-B2789E9A31F2Q36165438-45894955-CC2C-44C7-8B63-04D944E191FDQ36234238-9E6D33F4-0237-410F-8F67-98AB416080B6Q36243660-2E928366-1A29-4596-8D27-65FF3911F192Q36310074-60B947AC-F7A4-4260-9925-65D6633951D1Q36366731-7C37FD7C-83A3-46E4-B859-936A6ECCDAB9Q36367355-461CB33E-087B-455E-9B90-BD0AF22BA177Q36421863-9C330D92-D8D2-4A12-B86E-788D999F23E0Q36733510-DCE9CD14-DBDE-4084-B09A-8FE8CB49C1EAQ36926261-706ED1C0-61F0-4833-A785-FDFFD77907BEQ36953261-61C7A054-6089-41D3-8ECA-4572EE651C20Q37251093-96E1262A-EF19-44F6-A2F7-F0726AE61686Q37867227-6BE834ED-1B7B-4A53-BBC6-70545D103D45Q38044684-D5C2B441-48F4-4477-A9F2-C08439362717Q38598513-2FAE22FA-5E69-44E4-B1E4-27B5104C417FQ39141240-A6657274-4C99-4870-9666-9E3CBA0DDEF4Q39420404-E30F0A69-D7C0-4D68-827E-6D17B75664C9Q39768988-B1FBF234-7F4E-48B5-B00D-4CB40B173017Q39962349-29B777BA-AB29-4FE2-A86F-4B89DAF8D19AQ41907633-D7A345FC-4D67-4A07-A53D-DA3672371F2BQ42620886-6ADE4C12-3E2D-4374-B150-D57094D0CC42Q47744626-32D8A92D-676D-42AE-ABB0-A4C22FF6D3D7
P2860
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
@ast
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
@en
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
@nl
type
label
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
@ast
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
@en
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
@nl
prefLabel
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
@ast
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
@en
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
@nl
P2093
P1476
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
@en
P2093
Daniele Piomelli
Laura Righetti
Pasqua Dipasquale
Silvana Gaetani
Vincenzo Cuomo
P356
10.1016/S0074-7742(09)85005-8
P577
2009-01-01T00:00:00Z